Targeting phosphoinositide 3-kinase: moving towards therapy

Area of Science:

• Cellular signaling and molecular biology
• Pharmacology and drug discovery
• Oncology and immunology

Background:

• Phosphoinositide 3-kinases (PI3K) are crucial regulators of fundamental cellular processes, including growth, survival, and migration.
• PI3K pathway dysregulation, through mutations or altered protein levels, is implicated in cancer and inflammatory conditions.
• Specific PI3K isoforms, like PI3Kgamma and PI3Kdelta, play key roles in immune cell function and inflammatory responses.

Purpose of the Study:

• To review the disease-relevant functions of isoform-specific PI3K.
• To analyze the progress of pharmaceutical targeting of the PI3K pathway.
• To discuss safety concerns associated with PI3K inhibitors.

Main Methods:

• Literature review of PI3K pathway deregulation in disease.
• Analysis of genetic targeting studies in mouse models.
• Review of over 400 patents related to pharmaceutical targeting of PI3K.

Main Results:

• PI3K pathway deregulation is linked to cancer cell proliferation.
• Isoform-specific PI3K targeting has shown efficacy in preclinical models of rheumatoid arthritis and lupus erythematosus.
• Several PI3K pathway inhibitors are in early-phase clinical trials for cancer and myocardial infarction.

Conclusions:

• Targeting the PI3K pathway holds significant therapeutic potential for various diseases.
• Isoform-specific inhibition is a key strategy, but requires careful management of safety concerns.
• Ongoing clinical trials indicate progress in translating PI3K-targeted therapies.